IpIBA seminar series 2022/2023 “Intravenous delivery of BCG into the lung enables antitumor immunity”
Administration of BCG into the bladder was one of the first immunotherapies approved by the FDA and nowadays is still the treatment of choice for a subset of non-muscle invasive bladder cancer patients. Recently, it was shown that systemic administration of BCG by the intravenous (IV) route is well-tolerated and highly effective at preventing tuberculosis infection in a Rhesus macaque model. Here, we show that systemic administration of BCG by the IV route in a therapeutic scenario slows tumor growth and extends mouse survival in mouse models of B16-F10 lung metastasis and in an orthotopic LLC lung cancer model by enhancing both antitumoral innate and adaptive immune responses.
CIBA, main meeting room, and online via zoom.
Importante las plazas son limitadas: 100 presencial y 100 modalidad on line. Si participa de forma presencial no hace falta realizar inscripción on line.